Two FDA Warning Letters September 2025 and February 2026 The FDA issued formal warning letters to FitRX LLC, doing business as Zealthy, in September 2025 and again on February 20, 2026
Julius Few, MD, a Sciton luminary, key aesthetic industry opinion leader, and a leading plastic surgeon, told Allure Magazine that patients on GLP-1s often have skin that doesnt snap back the way it typically does in nonGLP-1 weight loss
At Melbourne Pharma, we offer proprietary formulations designed using the most popular and well-studied ingredients for anti-aging skincare.
SmartCardia has received US Food and Drug Administration (FDA) clearance for its seven-lead real-time electrocardiogram (ECG) monitoring patch and cloud platform
The skyrocketing popularity of the diabetes drug Ozempic has put a heavy burden on public spending in Denmark, the home country of the drugs producer Novo Nordisk
Weight loss injections work by mimicking natural hormones that regulate appetite and blood sugar